Journal article
Paracetamol use in early life and asthma: Prospective birth cohort study
AJ Lowe, JB Carlin, CM Bennett, CS Hosking, KJ Allen, CF Robertson, C Axelrad, MJ Abramson, DJ Hill, SC Dharmage
BMJ Online | BMJ PUBLISHING GROUP | Published : 2010
DOI: 10.1136/bmj.c4616
Open access
Abstract
Objective: To determine if use of paracetamol in early life is an independent risk factor for childhood asthma. Design: Prospective birth cohort study. Setting: Melbourne Atopy Cohort Study. Participants: 620 children with a family history of allergic disease, with paracetamol use prospectively documented on 18 occasions from birth to 2 years of age, followed until age 7 years. Main outcome measures: The primary outcome was childhood asthma, ascertained by questionnaire at 6 and 7 years. Secondary outcomes were infantile wheeze, allergic rhinitis, eczema, and skin prick test positivity. Results: Paracetamol had been used in 51% (295/575) of children by 12 weeks of age and in 97% (556/575) by..
View full abstractGrants
Funding Acknowledgements
Dairy Australia, CRC for Asthma, and VicHealth supported AJL during his PhD, when the work presented in the manuscript was first developed. AJL, SCD, and KJA are supported by the National Health and Medical Research Council. Nestec, a subsidiary of Nestle Australia, provided staff funding for the first six years of the study. The funding bodies had no role in the design, analysis, conduct, or reporting of the study. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources.All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) DJH has received support from Nestec (a subsidiary of Nestle Australia) for the submitted work; (2) within the previous 3 years, SCD has received a grant from GlaxoSmithKline for unrelated work, MJA received funding from Reckitt Benckiser for an unrelated research project, CFR is on the GlaxoSmithKline Pediatric Asthma Scientific Board, and MJA is on the GlaxoSmithKline Scientific Advisory Committee for the Australian Asthma Study, and these companies might have an interest in the submitted work; (3) all authors their spouses, partners, or children have no other financial relationships that may be relevant to the submitted work; and (4) all authors have no non-financial interests that may be relevant to the submitted work.